{
    "clinical_study": {
        "@rank": "148079", 
        "arm_group": {
            "arm_group_label": "Dalantercept plus sorafenib", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and tolerability of dalantercept plus\n      sorafenib in patients with advanced hepatocellular carcinoma (HCC) to determine the\n      recommended dose level of dalantercept in combination with sorafenib."
        }, 
        "brief_title": "Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed, locally advanced or metastatic HCC.\n\n          -  Child-Pugh Score A (5-6)\n\n          -  At least one target lesion that has not been treated with local therapy and is\n             measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n\n          -  Life expectancy of at least 12 weeks.\n\n          -  Able to tolerate oral therapy.\n\n          -  Appropriate clinical laboratory values within 72 hours prior to study day 1:\n\n          -  Females of child bearing potential (defined as sexually mature women who have not\n             undergone hysterectomy or bilateral oophorectomy, or are not naturally postmenopausal\n             \u2265 24 consecutive months) must have negative urine or blood pregnancy test prior to\n             enrollment and use adequate birth control methods (abstinence, oral contraceptives,\n             barrier method with spermicide, or surgical sterilization) during study\n             participation.  Males must agree to use a latex condom during any sexual contact with\n             females of child bearing potential while participating in the study and for 12 weeks\n             following the last dose of dalantercept, even if he has undergone a successful\n             vasectomy.  Patients must be counseled concerning measures to be used to prevent\n             pregnancy and potential toxicities prior to the first dose of dalantercept.\n\n        Exclusion Criteria:\n\n          -  Mixed tumor histology\n\n          -  Prior systemic therapy for metastatic disease.\n\n          -  Adjuvant therapy < 6 months prior to study day 1.\n\n          -  Prior treatment with dalantercept or other agent targeting the ALK1 pathway.\n\n          -  Prior treatment with sorafenib or other RAF/VEGF targeted therapies.\n\n          -  Hepatic radiation, chemoembolization, and radiofrequency ablation < 4 weeks prior to\n             study day 1.\n\n          -  Palliative radiation therapy to metastatic sites of disease < 2 weeks prior to study\n             day 1.\n\n          -  Interferon therapy < 4 weeks prior to study day 1.\n\n          -  Uncontrolled Hepatitis B despite appropriate therapy.\n\n          -  Clinically significant pulmonary, endocrine, neurologic, hematologic,\n             gastrointestinal (GI), autoimmune, psychiatric or genitourinary disease unrelated to\n             HCC that in the judgment of the investigator should preclude treatment with\n             dalantercept or sorafenib.\n\n          -  Known HIV infection.\n\n          -  Clinically significant cardiovascular risk\n\n          -  Clinically significant active pulmonary risk\n\n          -  Known active gastrointestinal (GI) bleeding.\n\n          -  Known bleeding diathesis Known history of hereditary hemorrhagic telangiectasia\n             (HHT).\n\n          -  History of another primary cancer, with the exception of:\n\n               1. Curatively resected non melanoma skin cancer.\n\n               2. Curatively treated cervical carcinoma in situ.\n\n               3. Other primary solid tumor with no known active disease in the opinion     of the\n                  investigator that will not affect patient outcome in the setting of current HCC\n                  diagnosis.\n\n          -  Major surgery within 4 weeks prior to study day 1 Active infection Anti-coagulation\n             therapy Concomitant treatment with potent CYP3A4 inducers\n\n          -  Peripheral edema \u2265 grade 2 within 2 weeks prior to study day 1.\n\n          -  History of recurrent ascites requiring paracentesis within 4 weeks of study day 1.\n\n          -  History of severe (using the National Cancer Institute Common Toxicity Criteria for\n             Adverse Events, version 4.0 [NCI-CTCAE] v4 current minor version \u2265 grade 3) allergic\n             or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024087", 
            "org_study_id": "A041-05", 
            "secondary_id": "ACE-041"
        }, 
        "intervention": {
            "arm_group_label": "Dalantercept plus sorafenib", 
            "description": "Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.", 
            "intervention_name": "Dalantercept plus sorafenib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York"
                }, 
                "name": "Acceleron Investigative Site"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Open Label Study of Dalantercept Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma", 
        "overall_contact": {
            "email": "clinicaltrials041@acceleronpharma.com", 
            "last_name": "Clinical Trials Manger"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessed by monitoring AEs using the current active minor version on the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 4.0 (NCI-CTCAE v4 current minor version), physical examinations, vital signs, clinical laboratory test, ECHO, ECG and ADA testing; through final study visit, up to approximately 20 weeks from first dose of dalantercept.", 
            "measure": "Number of participants with Adverse Events as a measure of safety and tolerability.", 
            "safety_issue": "Yes", 
            "time_frame": "up to approximately 20 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024087"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Patents will be assessed for efficacy using RECIST v1.1 evaluating response rate; PFS measured from date of randomization through final study visit (up to approximately 20 weeks from first dose of dalantercept), or until disease progression.", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 20 weeks"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 20 weeks"
            }, 
            {
                "description": "Patents will be assessed using RECIST v1.1 evaluating response rate; TTP measured from date of randomization through final study visit (up to approximately 20 weeks from first dose of dalantercept), or until disease progression.", 
                "measure": "Time to progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 20 weeks"
            }, 
            {
                "description": "Patents will be assessed using RECIST v1.1 evaluating response rate; DCR from date of randomization through final study visit (up to approximately 20 weeks from first dose of dalantercept), or until disease progression.", 
                "measure": "Disease control rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 20 weeks"
            }, 
            {
                "description": "Through final study visit, up to approximately 20 weeks from first dose of dalantercept.", 
                "measure": "PD biomarker activities (e.g., ALK1 expression on new or archived tumor biopsy tissue; BMP9/10 levels in serum)", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 20 weeks"
            }
        ], 
        "source": "Acceleron Pharma, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Acceleron Pharma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}